A prospective study of cerebrospinal fluid concentrations of rituximab in primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021415

Enrollment

Unknown

Registered

2019-02-20

Start date

2016-12-05

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

craniotomy PCNSL (C-PSNCL) group:Induction therapy for PCNSL consisted of six cycles R-MT

stereotactic biopsy (S-PCNSL) group:Induction therapy for PCNSL consisted of six cycles R-MT

Eligibility

Sex/Gender

All

Age

14 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 14 to 70 years, all patients should be HIV-1 negative and newly diagnosed, histologically confirmed B-cell PCNSL. Patients with PCNSL were divided into craniotomy PCNSL (C-PSNCL) group and stereotactic biopsy (S-PCNSL) group according to the methods of diagnosis. All patients signed written informed consent before participation and the protocol was approved by the institutional review board.

Exclusion criteria

Exclusion criteria: Participated in other clinical trials in the last 3 months; Secondary or transforming lymphoma; CD20 negative; Systemic b-cell lymphoma; Active infection; Severe mental illness; Lactation or pregnancy women

Design outcomes

Primary

Measure	Time frame
The concentration of rituximab in cerebrospinal fluid;	—

Secondary

Measure	Time frame
Objective Response Rate;5-year overall survival;5-year progression free survival;	—

Countries

China

Contacts

Public ContactTongyu Lin

Sun Yat-sen University Cancer Center

tongyulin@hotmail.com+86 13926400320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026